Dynasty Wealth Management LLC Decreases Stock Holdings in Abbott Laboratories (NYSE:ABT)

Dynasty Wealth Management LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 34,724 shares of the healthcare product maker’s stock after selling 190 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,928,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Peterson Financial Group Inc. bought a new stake in Abbott Laboratories during the third quarter valued at about $32,000. Valued Wealth Advisors LLC grew its position in Abbott Laboratories by 78.4% in the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after acquiring an additional 127 shares in the last quarter. Wingate Wealth Advisors Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth $34,000. Highline Wealth Partners LLC bought a new position in Abbott Laboratories during the 3rd quarter valued at about $37,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $37,000. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABT. Barclays reaffirmed an “overweight” rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday, January 21st. Argus raised Abbott Laboratories to a “strong-buy” rating in a research note on Tuesday, January 28th. Evercore ISI lifted their target price on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research report on Thursday, January 2nd. Finally, Stifel Nicolaus increased their price target on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.06.

Abbott Laboratories Stock Performance

Shares of ABT opened at $135.89 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market cap of $235.67 billion, a PE ratio of 17.76, a P/E/G ratio of 2.52 and a beta of 0.75. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $136.99. The stock has a fifty day moving average price of $122.60 and a 200-day moving average price of $117.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. The company had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.19 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.74%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.10% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.